5-乙基-5-(1-哌啶基)巴比妥酸 | 509-87-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 5-乙基-5-(1-哌啶基)巴比妥酸
• 英文名称: Piperidinethylbarbitursaeure
• 英文别名: 5-Ethyl-5-piperidino-barbitursaeure；5-ethyl-5-(piperidin-1-yl)-1,3-diazinane-2,4,6-trione；5-ethyl-5-(piperidin-1-yl)barbituric acid；5-ethyl-5-piperidin-1-yl-pyrimidine-2,4,6-trione；5-ethyl-5-(1-piperidinyl)-2,4,6(1H,3H,5H)-pyrimidinetrione；5-Aethyl-5-piperidino-barbitursaeure；5-ethyl-5-piperidino-barbituric acid；Eldoral；5-ethyl-5-piperidin-1-yl-1,3-diazinane-2,4,6-trione
• CAS: 509-87-5
• 化学式: C₁₁H₁₇N₃O₃
• 分子量: 239.274
• InChiKey: ZFVLHMJCLWOOOY-UHFFFAOYSA-N

物化性质

• 熔点：
  215°C
• 沸点：
  381.93°C (rough estimate)
• 密度：
  1.1771 (rough estimate)
• 溶解度：
  0.01 M

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  78.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-乙基-5-(1-哌啶基)巴比妥酸 、 硫酸二甲酯 生成 5-ethyl-1-methyl-5-piperidino-barbituric acid
  参考文献：
  名称：

  DE606084

  摘要：

  公开号：
• 作为产物：
  描述：

  哌啶 、 5-bromo-5-ethyl-pyrimidine-2,4,6-trione 生成 5-乙基-5-(1-哌啶基)巴比妥酸
  参考文献：
  名称：

  US2078323

  摘要：

  公开号：

文献信息

• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• [EN] 18F-LABELLED BARBITURATE COMPOUNDS FOR USE AS POSITRON EMISSION IMAGING AGENTS<br/>[FR] COMPOSÉS BARBITURIQUES MARQUÉS AU 18F, CONVENANT COMME AGENTS D'IMAGERIE PAR ÉMISSION DE POSITRONS
  申请人：UNIV ABERDEEN

  公开号：WO2013038153A1

  公开（公告）日：2013-03-21

  The present invention relates generally to the field of diagnostic methods. More specifically, the present invention pertains to certain 18F-labelled barbiturate compounds of the following formula (collectively referred to herein as "18F-fluorinated barbiturate compounds" and "18FBAR compounds") that bind to metals, for example, metals associated with protein aggregates, and as such are useful as imaging agents for positron emission imaging (e.g., positron emission tomography (PET) imaging) used in the diagnosis and monitoring of conditions involving these aggregates, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). These compounds also bind strongly to GABAA receptors and hence are also useful as imaging agents for positron emission tomography (PET) imaging used in the diagnosis, monitoring and study of diseases involving dis-regulation of these receptors, including epilepsy, schizophrenia, and mood disorders (e.g., anxiety).

  本发明通常涉及诊断方法领域。更具体地说，本发明涉及以下化学式的某些18F标记的巴比妥化合物（以下统称为“18F氟代巴比妥化合物”和“18FBAR化合物”），这些化合物结合到金属，例如与蛋白聚集物相关的金属，并因此可用作正电子发射成像（例如正电子发射断层扫描（PET）成像）的成像剂，用于诊断和监测涉及这些聚集物的疾病，包括阿尔茨海默病（AD）、帕金森病（PD）和亨廷顿病（HD）。这些化合物还强烈结合到GABAA受体，因此也可用作正电子发射断层扫描（PET）成像的成像剂，用于诊断、监测和研究涉及这些受体失调的疾病，包括癫痫、精神分裂症和情绪障碍（例如焦虑）。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• Tamper-resistant pharmaceutical dosage forms and process for making same
  申请人：ExxPharma Therapeutics LLC

  公开号：US10010620B2

  公开（公告）日：2018-07-03

  A process for the preparation of an erodible tamper-resistant dosage form that comprises a therapeutic agent-substrate complex embedded in a thermo-formable matrix, such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive. The dosage form provides resistance to intentional or unintentional tampering such as chewing, crushing and grinding, and volatilization.

  一种用于制备可侵蚀防篡改剂型的工艺，该剂型包括嵌入热成型基质中的治疗剂-基质复合物，该复合物包括至少一种治疗剂与至少一种基质结合以形成治疗剂-基质复合物。至少一种基质选自聚电解质、有机反离子、原药的药理学惰性有机成分、包涵化合物和无机吸附剂；热成型基质包括一种或多种热塑性聚合物，以及可选的至少一种药物添加剂。该剂型可防止有意或无意的篡改，如咀嚼、粉碎和研磨以及挥发。
• Transdermal drug delivery device including an occlusive backing
  申请人：Noven Pharmaceuticals, Inc.

  公开号：US10231938B2

  公开（公告）日：2019-03-19

  A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

  一种透皮给药系统，用于局部应用一种或多种活性剂，这些活性剂包含在一个或多个聚合物和/或粘合剂载体层中，靠近一个不含药物的聚合物背层，该背层可通过调节聚合物背层的湿气透过率来控制透皮给药系统的给药速率和概况。